ReviewLeukemia2004
The rise and fall of genomic methylation in cancer.
Review in Leukemia, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Methylation reprogramming associated with aggressive prostate cancer and ancestral disparities.Molecular systems biology · 2025Article
- KMT2A degradation is observed in decitabine-responsive acute lymphoblastic leukemia cells.Molecular oncology · 2025Article
- Specific glioblastoma multiforme prognostic-subtype distinctions based on DNA methylation patterns.Cancer gene therapy · 2020Article
- Specific Glioma Prognostic Subtype Distinctions Based on DNA Methylation Patterns.Frontiers in genetics · 2019Article
- Driver mutations of cancer epigenomes.Protein & cell · 2014Article
- Oxidative stress due to radiation in CD34(+) hematopoietic progenitor cells: protection by IGF-1.Journal of radiation research · 2012Article
- Array-based genomic resequencing of human leukemia.Oncogene · 2010Article
- Estrogen regulates DNA methyltransferase 3B expression in Ishikawa endometrial adenocarcinoma cells.Molecular biology reports · 2009Article
- Blocking beta-catenin binding to the ZBP1 promoter represses ZBP1 expression, leading to increased proliferation and migration of metastatic breast-cancer cells.Journal of cell science · 2009Article
- Genome organization, instabilities, stem cells, and cancer.Journal of stem cells & regenerative medicine · 2009Article
- Epigenetic regulation of protein tyrosine phosphatases: potential molecular targets for cancer therapy.Cancer gene therapy · 2005Review
- Gene expression profiling of epithelial ovarian tumours correlated with malignant potential.Molecular cancer · 2004Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Changes in genomic methylation and its significance in carcinogenesis is in the spotlight once again, though the focus is not on the usual suspects, DNA hypermethylation and tumour suppressor gene (TSG) silencing. Several recent reports provide compelling evidence of the relevance of genomic hypomethylation in cancer. These findings provide the best evidence so far that links the loss of DNA methylation and chromosomal instability with cancer development. This review article discusses these recent findings and reflects on the antithetical association between DNA methylation and carcinogenesis and the re-examination of studies performed almost two decades ago.
Indexed as
Identifiers
14628069What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.